Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interaction between Cdc37 and Cdk4 in human cells

L Lamphere1, F Fiore, X Xu

  • 1Mitotix, Inc., Cambridge, Massachusetts 02139, USA.

Oncogene
|April 24, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transgenic overexpression of miR-486 and sAnk1.5 does not alter glucose handling in mice.

Biochimica et biophysica acta. Molecular cell research·2025
Same author

Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET).

ESMO open·2025
Same author

Bioinspired Collagen/κ-Carrageenan 3D Matrix for <i>In Vitro</i> Modeling of Vascular Calcification.

ACS biomaterials science & engineering·2025
Same author

Mobility of Membrane Lipids and Proteins at the Animal and Vegetal Pole of the Sea Urchin Egg: (sea urchin/polarity/plasma membrane/translational mobility/fluorescence microphotolysis, photobleaching).

Development, growth & differentiation·2023
Same author

Ryanodine Activates Sea Urchin Eggs: (sea urchin egg/activation/ryanodine/inositol phosphate/heparin).

Development, growth & differentiation·2023
Same author

Skeletal muscle overexpression of sAnk1.5 in transgenic mice does not predispose to type 2 diabetes.

Scientific reports·2023
Same journal

SRD5A3-mediated aberrant N-glycosylation of SCARA5 promotes ferroptosis in lung adenocarcinoma.

Oncogene·2026
Same journal

Aberrant splicing in human cancer shows possible functional impact on transcription factors.

Oncogene·2026
Same journal

The crosstalk between RNA m6A modification and protein lactylation: emerging insights into tumor progression.

Oncogene·2026
Same journal

Correction: Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.

Oncogene·2026
Same journal

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

Oncogene·2026
Same journal

Histone lactylation-driven IGF2BP3 promotes intrahepatic cholangiocarcinoma progression via SPP1/CD44-dependent macrophage polarization.

Oncogene·2026
See all related articles

Researchers identified Cdc37 as a novel protein interacting with Cyclin-dependent kinase 4 (Cdk4). Cdc37 facilitates Cdk4/cyclin D1 complex assembly and competes with p16 for Cdk4 binding.

Area of Science:

  • Molecular Biology
  • Cell Cycle Regulation
  • Protein Interactions

Background:

  • Cyclin-dependent kinases (Cdks) regulate cell cycle progression.
  • Cdk4, in complex with D-type cyclins, is a key regulator of the G1 to S phase transition.
  • Dysregulation of Cdk4 activity is implicated in various cancers.

Purpose of the Study:

  • To identify novel interacting partners of Cdk4.
  • To characterize the interaction between Cdk4 and its human homologue of yeast Drosophila CDC37 gene product, Cdc37.
  • To elucidate the functional role of Cdc37 in Cdk4/cyclin D1 complex formation and kinase activity.

Main Methods:

  • Yeast two-hybrid system for identifying protein-protein interactions.
  • In vitro kinase assays to assess Cdk4/cyclin D1 activity.

Related Experiment Videos

  • Co-immunoprecipitation to confirm protein binding.

    • Main Results:

    • The yeast two-hybrid system identified Cdc37 as a novel Cdk4 interacting protein.
    • Cdc37 specifically interacts with Cdk4 and Cdk6, but not other tested Cdks (Cdc2, Cdk2, Cdk3, Cdk5) or cyclins.
    • Cdc37 facilitates the assembly of Cdk4/cyclin D1 complexes in vitro.
    • Cdc37 competes with the inhibitor p16 for binding to Cdk4.

    Conclusions:

    • Cdc37 is a novel binding partner of Cdk4 and Cdk6.
    • Cdc37 plays a role in facilitating Cdk4/cyclin D1 complex formation.
    • Cdc37 may be involved in the mechanism by which p16 inhibits Cdk4 activity by interfering with complex assembly.